BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1054 related articles for article (PubMed ID: 20060824)

  • 21. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.
    Peng GS; Li G; Tzeng NS; Chen PS; Chuang DM; Hsu YD; Yang S; Hong JS
    Brain Res Mol Brain Res; 2005 Mar; 134(1):162-9. PubMed ID: 15790540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death.
    Signore AP; Weng Z; Hastings T; Van Laar AD; Liang Q; Lee YJ; Chen J
    J Neurochem; 2006 Jan; 96(2):428-43. PubMed ID: 16336625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis in primary cultures of E14 rat ventral mesencephala: time course of dopaminergic cell death and implications for neural transplantation.
    Branton RL; Clarke DJ
    Exp Neurol; 1999 Nov; 160(1):88-98. PubMed ID: 10630193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity.
    Carrasco E; Casper D; Werner P
    J Neurosci Res; 2005 Jul; 81(1):121-31. PubMed ID: 15931668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
    Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
    Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
    Wang JY; Wu JN; Cherng TL; Hoffer BJ; Chen HH; Borlongan CV; Wang Y
    Brain Res; 2001 Jun; 904(1):67-75. PubMed ID: 11516412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional effect of FGF2- and FGF8-expanded ventral mesencephalic precursor cells in a rat model of Parkinson's disease.
    Jensen P; Pedersen EG; Zimmer J; Widmer HR; Meyer M
    Brain Res; 2008 Jul; 1218():13-20. PubMed ID: 18513704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
    Locke CJ; Fox SA; Caldwell GA; Caldwell KA
    Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of GDNF on differentiation of cultured ventral mesencephalic dopaminergic and non-dopaminergic calretinin-expressing neurons.
    Schaller B; Andres RH; Huber AW; Meyer M; Pérez-Bouza A; Ducray AD; Seiler RW; Widmer HR
    Brain Res; 2005 Mar; 1036(1-2):163-72. PubMed ID: 15725414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Agrawal AK
    Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
    Zbarsky V; Datla KP; Parkar S; Rai DK; Aruoma OI; Dexter DT
    Free Radic Res; 2005 Oct; 39(10):1119-25. PubMed ID: 16298737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease.
    McLeod M; Hong M; Mukhida K; Sadi D; Ulalia R; Mendez I
    Eur J Neurosci; 2006 Jul; 24(2):361-70. PubMed ID: 16903847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.
    Winter C; Hosmann K; Harnack D; Meissner W; Paul G; Morgenstern R; Kupsch A
    Synapse; 2006 Jul; 60(1):69-80. PubMed ID: 16598703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.
    Zhang W; Qin L; Wang T; Wei SJ; Gao HM; Liu J; Wilson B; Liu B; Zhang W; Kim HC; Hong JS
    FASEB J; 2005 Mar; 19(3):395-7. PubMed ID: 15596482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model three-dimensional culture system for mammalian dopaminergic precursor cells: application for functional intracerebral transplantation.
    Spector DH; Boss BD; Strecker RE
    Exp Neurol; 1993 Dec; 124(2):253-64. PubMed ID: 7904568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
    Harvey BK; Mark A; Chou J; Chen GJ; Hoffer BJ; Wang Y
    Brain Res; 2004 Oct; 1022(1-2):88-95. PubMed ID: 15353217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.
    Stahl K; Mylonakou MN; Skare Ø; Amiry-Moghaddam M; Torp R
    Brain Res; 2011 Mar; 1378():105-18. PubMed ID: 21236244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.